ClinicalTrials.gg
CompletedNCT02935699Updated Nov 27, 2019Results posted

Clinical Trial Comparing JDP-205 to Diphenhydramine Injection for the Treatment of Acute Urticaria

A Phase 3 interventional study of Test Drug (JDP-205) and Active Control (Diphenhydramine) in Acute Urticaria, sponsored by JDP Therapeutics, Inc.. Completed at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-27.

Sponsored by JDP Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
262
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 47 studies in Urticaria with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Urticaria · United States.

Enrollment
2nd of 37
262 · median 39
Started
2017
with 2 others
Phase 3
6 of 47
none open now
Registered
28th of 47
by date
Lead sponsor
2 of 47
JDP Therapeutics, Inc.

Among the 47 studies in Urticaria with a site in United States, this one is the 2nd largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2017, is one of 6 in phase 3, and was the 28th registered.

Urticaria

148 studies on the registry are indexed under Urticaria; 19 are open to participants now.

Browse Urticaria studies →

Open to participants now

4 of the 47 studies in Urticaria with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Urticaria studies recruiting now, 3 (25%) set no upper age limit and 6 (50%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Urticaria with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, parallel group, randomized, double-blind, active controlled, Phase III clinical study of cetirizine injection, 10 mg/mL, compared to diphenhydramine injection, 50 mg/mL (Benadryl or generic equivalent) with acute urticaria requiring treatment.

Read the detailed description

This was a multi-center, parallel group, randomized, double-blind, active controlled, Phase III clinical trial of cetirizine injection 10 mg/mL versus diphenhydramine injection 50 mg/mL (Benadryl or generic equivalent) in approximately 256 subjects who either presented to Emergency Departments, hospitals, allergy clinics or Urgent Care Centers with acute urticaria, or developed acute urticaria following allergen challenge at an Allergy Clinic.

Patients signed an informed consent and were evaluated for eligibility for inclusion to treat. Eligible subjects were assessed for baseline characteristics, medical and surgical histories, concomitant medications and given a brief physical exam.

Subjects were then randomized, in a 1:1 ratio, to blindly receive either cetirizine 10 mg/mL injection or diphenhydramine 50 mg/mL injection.

Efficacy assessments included patient-rated severity of pruritus, physician assessments of extent of urticaria/erythema, and sedation score. Subjects remained in the treatment center for at least after the 1 hr assessment, after which they may have been discharged at the physician's discretion.

Safety was monitored through the reporting of adverse events for up to 28 days following treatments and by monitoring vital signs at planned intervals from admission into the treating facility until readiness for discharge. After 24 and 48 hrs after discharge, subjects were contacted by phone for follow-up questions regarding recurrence of symptoms, new symptoms, additional medication taken, side effects from medication taken after discharge, relapse requiring a return to treatment center, and return to normal activities.

03

Conditions studied

  • Acute Urticaria

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients with a diagnosis of acute urticaria who need treatment with antihistamine to alleviate their symptoms;
  2. 18 years of age or older;
  3. Be willing and able to give ;
  4. Patients with a Patient rated Pruritus Severity Score ≥ 1

Exclusion criteria

Exclusion Criteria:

  1. Receipt of an drug or device, within the past 30 days;
  2. Patients in whom an antihistamine may be (e.g. narrow angle glaucoma, symptomatic prostatic hypertrophy);
  3. Patients who, in the opinion of the investigator, may not tolerate an IV injection of diphenhydramine 50 mg, or cetirizine 10 mg;
  4. Receipt of any antihistamine (H1 antagonist) within the past 2 hours regardless of the route of administration, e.g. diphenhydramine, cetirizine, loratadine, fexofenadine, levocetirizine, desloratadine;
  5. Receipt of an H2 antagonist within the past 2 hours;
  6. Receipt of doxepin within the past 2 hours; doxepin is an antidepressant, but it also has antihistamine properties;
  7. Receipt of by the oral, IV, IM, or inhalational routes route within the past 4 hours to manage an acute allergic reaction;
  8. Receipt of epinephrine (EpiPen or any other brand) within the past 20 minutes;
  9. Anaphylaxis prior to the acute anaphylactic symptoms having been treated.
  10. Has known allergy to hydroxyzine, cetirizine or levocetirizine, or diphenhydramine;
  11. Pregnancy or breastfeeding;
  12. Patients who have an acute allergic reaction to medication they are taking (e.g. antibiotics, NSAIDs, etc.) and who cannot stop the medication;
  13. Patients who, based on their medical history or in the opinion of the investigator, have chronic urticaria, hereditary angioedema, urticaria to antihistamines, or dermatological disease that interferes with evaluation of a therapeutic response;
  14. Any condition that in the view of the investigator makes the subject unsuitable for enrollment in this study;
  15. History of or other known immunodeficiency;
  16. Major medical or psychiatric illness, other than acute urticaria, at the time of presentation;
  17. Inability to provide .
  18. Patients on concomitant p-glycoprotein inhibitors
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
262 participants (actual)

Study arms

  • Experimental
    Test Drug

    JDP-205 Injection, 10 mg/mL, 1 mL

    Drug: Test Drug (JDP-205)

  • Active comparator
    Control

    Diphenhydramine Injection, 50 mg/mL, 1 mL

    Drug: Active Control (Diphenhydramine)

Interventions

  • Cetirizine, 10mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes

    Also known as: QUZYTTIR

  • Diphenhydramine Injection, 50 mg/mL;a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes

    Also known as: Benadryl

06

What researchers measure

Primary outcomes

  1. Change of Patient Rated Pruritus Score

    Change from baseline to 2 hours in patient-rated pruritus Severity score (values at 2 hours minus Baseline) Patient Pruritus Severity Score Ask the patient "How severely are your hives itching at the moment?" 0 = none 1. = mild (minimal awareness, easily tolerated) 2. = moderate (definite awareness, quite bothersome) 3. = severe (difficult to tolerate)

    Time frame: 2 hr

Secondary outcomes

  1. Number of Patients Who Needed to Return to Treatment Center

    Number of patients who needed to return to treatment center approximately 24 hours after discharge

    Time frame: up to 24 hrs

  2. Time to Discharge

    Time spent (hours) at the treatment center

    Time frame: up to 24 hours

  3. Patient Sedation Scores

    Patient Sedation Score at 2 hours Ask the patient "How drowsy do you feel at the moment?" 0 = None (Not drowsy at all) 1. = Mild (Slightly drowsy) 2. = Moderate (Quite drowsy) 3. = Severe (Extremely drowsy)

    Time frame: 2 hours

07

Results

Posted Nov 27, 2019

Participant flow

Participant flow — Overall Study
MilestoneTest DrugControl
Started127135
Completed127135
Not completed00

Outcome measures

PrimaryChange of Patient Rated Pruritus Score

Change from baseline to 2 hours in patient-rated pruritus Severity score (values at 2 hours minus Baseline) Patient Pruritus Severity Score Ask the patient "How severely are your hives itching at the moment?" 0 = none 1. = mild (minimal awareness, easily tolerated) 2. = moderate (definite awareness, quite bothersome) 3. = severe (difficult to tolerate)

Time frame:
2 hr
Reported as:
Mean · score on a scale
Change of Patient Rated Pruritus Score
score on a scaleTest DrugControl
Change of Patient Rated Pruritus Score-1.61 ± 0.944-1.50 ± 0.984
SecondaryNumber of Patients Who Needed to Return to Treatment Center

Number of patients who needed to return to treatment center approximately 24 hours after discharge

Time frame:
up to 24 hrs
Reported as:
Count of participants · Participants
Number of Patients Who Needed to Return to Treatment Center
ParticipantsTest DrugControl
Number of Patients Who Needed to Return to Treatment Center719
SecondaryTime to Discharge

Time spent (hours) at the treatment center

Time frame:
up to 24 hours
Reported as:
Mean · hours
Time to Discharge
hoursTest DrugControl
Time to Discharge1.71 ± 0.8682.07 ± 1.112
SecondaryPatient Sedation Scores

Patient Sedation Score at 2 hours Ask the patient "How drowsy do you feel at the moment?" 0 = None (Not drowsy at all) 1. = Mild (Slightly drowsy) 2. = Moderate (Quite drowsy) 3. = Severe (Extremely drowsy)

Time frame:
2 hours
Reported as:
Mean · score on a scale
Patient Sedation Scores
score on a scaleTest DrugControl
Patient Sedation Scores0.46 ± 0.7210.88 ± 0.955

Adverse events

Collected over 28 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Test Drug0/127 (0%)0/127 (0%)5/127 (3.9%)
Control0/135 (0%)1/135 (0.7%)18/135 (13.3%)
Most frequent serious events
Most frequent serious events
EventTest DrugControl
anaphylactic reactionImmune system disorders0/1271/135
Most frequent other events
Showing 10 of 18
Most frequent other events
EventTest DrugControl
DizzinessNervous system disorders0/1276/135
NauseaGastrointestinal disorders0/1274/135
Burning sensationNervous system disorders0/1272/135
PyrexiaInjury, poisoning and procedural complications0/1272/135
UrticariaSkin and subcutaneous tissue disorders0/1272/135
DysgeusiaNervous system disorders1/1271/135
ParaesthesiaNervous system disorders1/1270/135
PresyncopeNervous system disorders1/1270/135
HeadacheNervous system disorders1/1271/135
DyspepsiaGastrointestinal disorders1/1270/135

Baseline characteristics

Age, Continuous
Age, Continuous(years)Test DrugControlTotal
Mean39.0 ± 16.2839.2 ± 15.9639.1 ± 16.08
Sex: Female, Male
Sex: Female, Male(Participants)Test DrugControlTotal
Female7788165
Male504797
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Test DrugControlTotal
American Indian or Alaska Native000
Asian459
Native Hawaiian or Other Pacific Islander101
Black or African American414485
White6462126
More than one race172441
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Test DrugControlTotal
United States127135262
08

Study locations

4 sites
  • Univ of Cincinnati Medical Center
    Cincinnati, Ohio 45219, United States
  • Einstein Medical Center
    Philadelphia, Pennsylvania 19141, United States
  • City Doc Urgent Care center
    Dallas, Texas 75209, United States
  • Ottawa Hospital
    Ottawa, Ontario K1Y 4E9, Canada
09

References and documents

Publications

  • Abella BS, Berger WE, Blaiss MS, Stiell IG, Herres JP, Moellman JJ, Suner S, Kessler A, Klausner HA, Caterino JM, Du J. Intravenous Cetirizine Versus Intravenous Diphenhydramine for the Treatment of Acute Urticaria: A Phase III Randomized Controlled Noninferiority Trial. Ann Emerg Med. 2020 Oct;76(4):489-500. doi: 10.1016/j.annemergmed.2020.05.025. Epub 2020 Jul 9. PubMed 32653333 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Apr 2018, 13 months.

Results were first posted in Nov 2019, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2016
First posted
Oct 17, 2016
StartActual
Mar 1, 2017
Primary completionActual
Apr 30, 2018
CompletionActual
Apr 30, 2018
Results first posted
Nov 27, 2019
Last update
Nov 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02935699
Lead sponsor
JDP Therapeutics, Inc.
Responsible party
Sponsor
First posted
Oct 17, 2016
Start date
Mar 1, 2017
Primary completion
Apr 30, 2018
Completion
Apr 30, 2018
Results posted
Nov 27, 2019
Last update
Nov 27, 2019

Study contacts

JIE DU, PH.D.
study chair · JDP Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetirizine

Start the discussion